ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "MOA: CDH6-Targeted Antibody-Drug Conjugates "
Episode Synopsis
CME credits: 0.50
Valid until: 14-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/
Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.
Valid until: 14-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/
Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.
In God we trust